Sengenics is a precision medicine company that is revolutionizing the field of immunoprofiling. Their industry-first immunoprofiling technology utilizes a unique autoantigen-based platform, enabling the accelerated discovery of clinically relevant autoantibody biomarkers. This groundbreaking technology has far-reaching applications in various disease areas, including autoimmune disease, immuno-oncology, neurological disease, and infectious disease.

Sengenics offers a range of services and products to support biomarker discovery, patient stratification, response prediction, and diagnostics development. Their services include autoantibody biomarker profiling, oncology drug screening, vaccine development, and custom protein arrays. These services are underpinned by their patented KREX® protein folding technology and ORVAR® autoantigen discovery platform, which provide unique capabilities for biomarker discovery.

Sengenics is dedicated to advancing precision medicine and improving patient outcomes by leveraging cutting-edge immunoprofiling technologies and data-guided decision making. Their solutions empower researchers and clinicians to effectively navigate the complexities of biomarker discovery, leading to more personalized and targeted treatments. With their expertise and innovative technologies, Sengenics is at the forefront of precision medicine, driving the discovery of next-generation biomarkers